The Food and Drug Administration approved Revolution Medicines' promising pancreatic cancer drug on Aug. 26 after a clinical trial showed life expectancy nearly doubled for patients with disease that ...

A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized Phase III RASolute 302 trial comparing daraxonrasib to ...

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...

Please provide your email address to receive an email when new articles are posted on . Daraxonrasib nearly doubled survival vs. chemotherapy for pretreated patients with metastatic pancreatic cancer.

ARPI-based doublet regimens improve progression-free survival broadly, yet agent choice and magnitude of benefit can vary with age and comorbidity profiles, including heightened cardiovascular and ...